Существующие проблемы профилактики и лечения химиоиндуцированной периферической нейропатии: мировой опыт и собственные данные

Автор: Чиж Г.А., Рыков И.В., Орлова Д.С., Кузин С.О., Эльмурзаев А.Б., Шишкин А.Б., Богомолов В.В.

Журнал: Злокачественные опухоли @malignanttumors

Статья в выпуске: 1 т.14, 2024 года.

Бесплатный доступ

Химиоиндуцированная периферическая нейропатия (ХИПН) - осложнение, которое возникает у большинства пациентов при проведении противоопухолевой терапии с применением таксанов и препаратов платины. ХИПН включает в себя широкую палитру клинических проявлений. наиболее частыми из которых выступают нарушения чувствительности. У части пациентов проявления ХИПН сохраняются даже после завершения химиотерапии. Влияние на качество жизни, высокая распространенность ХИПН среди онкологических пациентов, делает актуальным поиск новых методов медикаментозной коррекции данного осложнения. В данном обзоре обсуждаются существующие проблемы в отношении медикаментозной профилактики и лечения ХИПН. Нами также представлен собственный опыт наблюдения за пациентами с химиоиндуцированной нейропатией. Опираясь на результаты наших наблюдений за пациентами, показано влияние данного осложнения на качество жизни пациентов, выходящее за рамки нарушения периферической сенсорной чувствительности. Это следует учитывать при дальнейшем изучении возможности медикаментозной коррекции данного нежелательного явления.

Еще

Химиотерапия, нейропатия, химиоиндуцированная периферическая нейропатия, таксаны, препараты платины, лечение нейропатии

Короткий адрес: https://sciup.org/140305811

IDR: 140305811 | DOI: 10.18027/2224-5057-2024-14-1-74-82

Список литературы Существующие проблемы профилактики и лечения химиоиндуцированной периферической нейропатии: мировой опыт и собственные данные

William J.G., Meena S.M., Jame A., et al. NCCN Guidelines insights: breast cancer, version 4.2023. J Natl Compr Canc Netw 2023;21(6):594-608. https://doi.org/10.6004/jnccn.2023.0031
Ettinger D.S., Wood D.E., Aisner D.L., et al. Non-Small Cell Lung Cancer. NCCN Guidelines Version 3.2023. J Natl Compr Canc Netw 2023;21(4):340-350. https://doi.org/10.6004/jnccn.2023.0020
NCCN Guidelines, Version 3.2023. Small Cell Lung Cancer. Available at: https://www.nccn.org/guidelines/nccn-guidelines/guidelines-detail?category =1&id =1462
NCCN Guidelines, Version 2.2023. Colon Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
NCCN Guidelines, Version 2.2023. Prostate Cancer. Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
Seretny M., Currie G.L., Sena E.S., et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 2014;155(12):2461-2470. https://doi.org/10.1016/j.pain.2014.09.020
Staff N.P., Grisold A., Grisold W., Windebank A.J. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol 2017;81(6):772-781. https://doi.org/10.1002/ana.24951
Hausheer F.H., Schilsky R.L., Bain S., et al. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 2006;33(1):15-49. https://doi.org/10.1053/j.seminoncol.2005.12.010
Park S.B., Lin C.S., Krishnan A.V., et al. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 2011;16(5):708-16. https://doi.org/10.1634/theoncologist.2010-0248
Molassiotis A., Cheng H.L., Leung K.T., et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav 2019;9(6):e01312. https://doi.org/10.1002/brb3.1312
Kalfakis N., Panas M., Karadima G., et al. Hereditary neuropathy with liability to pressure palsies emerging during vincristine treatment. Neurology 2002;59(9):1470-1. https://doi.org/10.1212/01.wnl.0000032505.45389.94
Chaudhry V., Chaudhry M., Crawford T.O., et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003;60(2):337-40. https://doi.org/10.1212/01.wnl.0000043691.53710.53
Chauvenet A.R., Shashi V., Selsky C., et al. Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 2003;25(4):316-20. https://doi.org/10.1097/00043426-200304000-00010
Gu J., Lu H., Chen C., et al. Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis. Support Care Cancer 2021;29(12):7461-7469. https://doi.org/10.1007/s00520-021-06321-7
Molassiotis A., Cheng H.L., Leung K.T., et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav 2019;9(6):e01312. https://doi.org/10.1002/brb3.1312
McWhinney-Glass S., Winham S.J., Hertz D.L., et al. Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clin Cancer Res 2013$19(20):5769-5776. https://doi.org/10.1158/1078-0432.CCR-13-0774
Jennaro T.S., Fang F., Kidwell K.M., et al. Vitamin D deficiency increases severity of paclitaxel-induced peripheral neuropathy. Breast Cancer Res Treat 2020;180(3):707-714. https://doi.org/10.1007/s10549-020-05584-8
Hershman D.L., Till C., Wright J.D., et al. Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials. J Clin Oncol 2016;34(25):3014-22. https://doi.org/10.1200/JCO.2015.66.2346
Solomon L.R. Functional vitamin B12 deficiency in advanced malignancy: implications for the management of neuropathy and neuropathic pain. Support Care Cancer 2016;24(8):3489-94. https://doi.org/10.1007/s00520-016-3175-5
EL-Najjar S.E., Naser I.A., AL-Wahidi K.M. Is Functional Vitamin B12 Deficiency a Risk Factor for the Development of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients? Research Square 2022. https://doi.org/10.21203/rs.3.rs-1667065/v2
Starobova H., Vetter I. Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. Front Mol Neurosci 2017;10:174. https://doi.org/10.3389/fnmol.2017.00174
Lee J.J., Swain S.M. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006;24(10):1633-42. https://doi.org/10.1200/JCO.2005.04.0543
de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18(16):2938-47. https://doi.org/10.1200/JCO.2000.18.16.2938
Park S.B., Goldstein D., Krishnan A.V., et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 2013;63(6):419-37. https://doi.org/10.3322/caac.21204. PMID: 2459086
Loprinzi C.L., Lacchetti C., Bleeker J., et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348. https://doi.org/10.1200/JCO.20.01399
Jordan B., Margulies A., Cardoso F., et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 2020;31(10):1306-1319. https://doi.org/10.1016/j.annonc.2020.07.003
Avallone A., Bimonte S., Cardone C., et al. Pathophysiology and Therapeutic Perspectives for Chemotherapy-induced Peripheral Neuropathy. Anticancer Res 2022;42(10):4667-4678. https://doi.org/10.21873/anticanres.15971
Akin E.J., Alsaloum M., Higerd G.P., et al. Paclitaxel increases axonal localization and vesicular trafficking of Nav1.7. Brain 2021;144(6):1727-1737. https://doi.org/10.1093/brain/awab113
Krukowski K., Ma J., Golonzhka O., et al. HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy. Pain 2017;158(6):1126-1137. https://doi.org/10.1097/j.pain.0000000000000893
Zheng H., Xiao W.H., Bennett G.J. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol 2011;232(2):154-61. https://doi.org/10.1016/j.expneurol.2011.08.016
Fumagalli G., Monza L., Cavaletti G., et al. Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy. Front Immunol 2021:11:626687. https://doi.org/10.3389/fimmu.2020.626687
Smith E.M., Pang H., Cirrincione C., et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013;309(13):1359-1367. https://doi.org/10.1001/jama.2013.2813
Farshchian N., Alavi A., Heydarheydari S., et al. Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy. Cancer Chemother Pharmacol 2018;82:787-793. https://doi.org/10.1007/s00280-018-3664-y
Matsuoka H., Clark K., Fazekas B., et al. Phase III, international, multicentre, double-blind, dose increment, parallel-arm, randomised controlled trial of duloxetine versus pregabalin for opioid-unresponsive neuropathic cancer pain: a JORTC-PAL16 trial protocol. BMJ Open 2022;12(2):e050182. https://doi.org/10.1136/bmjopen-2021-050182
Hershman D.L., Unger J.M., Crew K.D., et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 2013;31(20):2627-33. https://doi.org/10.1200/JCO.2012.44.8738
Kautio A.L., Haanpää M., Saarto T., Kalso E. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 2008;35(1):31-9. https://doi.org/10.1016/j.jpainsymman.2007.02.043
Gedlicka C., Scheithauer W., Schüll B., Kornek G.V. Effective treatment of oxaliplatin-induced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 2002;20(15):3359-61. https://doi.org/10.1200/JCO.2002.99.502
Guo Y., Jones D., Palmer J.L., et al. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer 2014;22(5):1223-31. https://doi.org/10.1007/s00520-013-2075-1
Dinicola S., Fuso A., Cucina A., et al. Natural products - alpha-lipoic acid and acetyl-L-carnitine - in the treatment of chemotherapy-induced peripheral neuropathy. Eur Rev Med Pharmacol Sci 2018;22(14):4739-4754. https://doi.org/10.26355/eurrev_201807_15534.2018
Mitchell P.L., Goldstein D., Michael M., et al. Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 2006;6(2):146-51. https://doi.org/10.3816/CCC.2006.n.032

Еще

Статья научная